BamSEC and AlphaSense Join Forces
Learn More

C4 Therapeutics Inc. – Material Contracts

NASDAQ: CCCC    
Share price (7/6/26): $4.14    
Market cap (7/6/26): $458 million

Material Contracts Filter

EX-10.1#
from 8-K 2 pages Amendment No. 2 to the 2020 Stock Option and Incentive Plan in Accordance With Section 16 of C4 Therapeutics, Inc. (The “Company”) 2020 Stock Option and Incentive Plan (The “Plan”), the Plan Is Hereby Amended as Follows, Subject to Approval of the Company’s Stockholders: 1. Section 1 of the Plan Is Hereby Amended to Include the Following as a New Definition: “Outstanding Shares” Means, as of a Specified Date, the Sum of (A) Number of Shares of Stock Issued and Outstanding and (B) the Number of Shares Issuable Pursuant to the Exercise of Any Outstanding, Pre-Funded Warrants to Acquire Shares for a Nominal Exercise Price. 2. the First Sentence of Section 3(a) of the Plan Is Hereby Deleted and Replaced as Follows: (A) Stock Issuable. the Maximum Number of Shares of Stock Reserved and Available for Issuance Under the Plan Shall Be 6,567,144 Shares (The “Initial Limit”), Subject to Adjustment as Provided in Section 3(c), Plus on January 1, 2021 and Each January 1 Thereafter, the Number of Shares of Stock Reserved and Available for Issuance Under the Plan Shall Be Cumulatively Increased by the Lesser of (I) Five Percent (5%) of the Outstanding Shares on the Immediately Preceding December 31 or (II) Such Lesser Number of Shares as Determined by the Administrator (The “Annual Increase”). This Amendment No. 2 to the Plan (This “Amendment”) Constitutes an Integral Part of the Plan. for All Purposes of This Amendment, Capitalized Terms Used Herein Without Definition Shall Have the Meanings Specified in the Plan, as the Plan Shall Be in Effect on the Date Hereof After Giving Effect to the Amendment. Except as Set Forth Herein, All of the Terms and Conditions of the Plan, as in Effect Prior to the Effectiveness of This Amendment, Shall Continue to Remain in Full Force and Effect as Originally Stated Therein. Date Approved by Board of Directors: April 21, 2026
12/34/56
EX-10.18
from 10-K 5 pages Material contract
12/34/56
EX-10.19
from 10-K 60 pages Material contract
12/34/56
EX-10.1
from 8-K/A 13 pages Redacted Redacted
12/34/56
EX-10.1
from 8-K 13 pages Redacted Redacted
12/34/56
EX-10.1
from 8-K 2 pages Material contract
12/34/56
EX-10.1
from 10-Q 60 pages Material contract
12/34/56
EX-10.19
from 10-K 7 pages Material contract
12/34/56
EX-10.18
from 10-K 111 pages Execution Version Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. License and Collaboration Agreement by and Between C4 Therapeutics, Inc. and Merck Sharp & Dohme LLC
12/34/56
EX-10.2
from 8-K 39 pages Stock Purchase Agreement Between C4 Therapeutics, Inc., Betta Investment (Hong Kong) Limited and Betta Pharmaceuticals Co., Ltd. Dated as of May 29, 2023
12/34/56
EX-10.1
from 8-K 71 pages License and Collaboration Agreement by and Between C4 Therapeutics, Inc., and Betta Pharmaceuticals Co., Ltd. May 29, 2023
12/34/56
EX-10.2
from 10-K 43 pages C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 8-K 36 pages Third Amendment to Lease
12/34/56
EX-10.13
from 10-K 9 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. First Amendment to Amended and Restated License Agreement
12/34/56
EX-10.11
from 10-K 4 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Amendment No. 1 to Collaborative Research and License Agreement
12/34/56
EX-10.3
from S-1/A 6 pages C4 Therapeutics, Inc. 2020 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 47 pages C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan
12/34/56
EX-10.14
from S-1 85 pages Material contract
12/34/56
EX-10.13
from S-1 101 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed
12/34/56
EX-10.12
from S-1 48 pages Collaboration and License Agreement
12/34/56